Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Emanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Biagio Pinchera & Ivan Gentile. (2020) Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opinion on Pharmacotherapy 21:3, pages 261-273.
Read now
Read now
Ivan Gentile, Riccardo Scotto, Emanuela Zappulo, Antonio Riccardo Buonomo, Biagio Pinchera & Guglielmo Borgia. (2016) Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 25:5, pages 557-572.
Read now
Read now
Parvez S. Mantry & Lakshmikant Pathak. (2016) Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert Review of Anti-infective Therapy 14:2, pages 157-165.
Read now
Read now
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2015) The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opinion on Drug Discovery 10:12, pages 1363-1377.
Read now
Read now
Nobuhisa Akamatsu, Yasuhiko Sugawara & Norihiro Kokudo. (2015) Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. Expert Review of Anti-infective Therapy 13:11, pages 1307-1317.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto & Guglielmo Borgia. (2015) Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety 14:10, pages 1631-1646.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo & Guglielmo Borgia. (2015) Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs 24:8, pages 1111-1121.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2015) Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 24:2, pages 239-251.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Giuseppina Minei, Filomena Morisco, Francesco Borrelli, Nicola Coppola & Guglielmo Borgia. (2014) Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management 10, pages 493-504.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola & Guglielmo Borgia. (2014) GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 12:10, pages 1179-1186.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo & Guglielmo Borgia. (2014) Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 12:9, pages 1033-1043.
Read now
Read now
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2014) Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs 23:9, pages 1211-1223.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2014) Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. Expert Review of Anti-infective Therapy 12:7, pages 763-773.
Read now
Read now
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo & Guglielmo Borgia. (2014) Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Review of Anti-infective Therapy 12:7, pages 775-782.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Emanuela Zappulo, Giuseppe Castaldo & Guglielmo Borgia. (2014)
MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opinion on Investigational Drugs 23:5, pages 719-728.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Giuseppe Castaldo & Guglielmo Borgia. (2014)
Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opinion on Investigational Drugs 23:4, pages 561-571.
Read now
Read now
Tabinda Burney & Geoffrey Dusheiko. (2011) Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Review of Anti-infective Therapy 9:2, pages 151-160.
Read now
Read now
MariaCássia Mendes-Corrêa & Marina Núñez. (2010) Management of HIV and hepatitis virus coinfection. Expert Opinion on Pharmacotherapy 11:15, pages 2497-2516.
Read now
Read now
Articles from other publishers (28)
Y. Li, S. Li, X. Duan, C. Yang, M. Xu & L. Chen. (2018) Hepatitis C: from discovery to cure. ISBT Science Series 13:3, pages 244-251.
Crossref
Crossref
Lisa Moni, Luca Banfi, Andrea Basso, Luca Carcone, Marcello Rasparini & Renata Riva. (2015) Ugi and Passerini Reactions of Biocatalytically Derived Chiral Aldehydes: Application to the Synthesis of Bicyclic Pyrrolidines and of Antiviral Agent Telaprevir. The Journal of Organic Chemistry 80:7, pages 3411-3428.
Crossref
Crossref
Ana Leitão, Marina Costa & Francisco Enguita. (2015) Unzippers, Resolvers and Sensors: A Structural and Functional Biochemistry Tale of RNA Helicases. International Journal of Molecular Sciences 16:2, pages 2269-2293.
Crossref
Crossref
Kerstin Herzer. (2015) Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World Journal of Hepatology 7:3, pages 532.
Crossref
Crossref
Pierre L. Beaulieu, Paul C. Anderson, Richard Bethell, Michael Bös, Yves Bousquet, Christian Brochu, Michael G. Cordingley, Gulrez Fazal, Michel Garneau, James R. Gillard, Stephen Kawai, Martin Marquis, Ginette McKercher, Marc-André Poupart, Timothy Stammers, Bounkham Thavonekham, Dominik Wernic, Jianmin Duan & George Kukolj. (2014) Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection. Journal of Medicinal Chemistry 57:23, pages 10130-10143.
Crossref
Crossref
Scott A. Read & Mark W. Douglas. (2014) Virus induced inflammation and cancer development. Cancer Letters 345:2, pages 174-181.
Crossref
Crossref
Oliver Hucke, René Coulombe, Pierre Bonneau, Mégan Bertrand-Laperle, Christian Brochu, James Gillard, Marc-André Joly, Serge Landry, Olivier Lepage, Montse Llinàs-Brunet, Marc Pesant, Martin Poirier, Maude Poirier, Ginette McKercher, Martin Marquis, George Kukolj, Pierre L. Beaulieu & Timothy A. Stammers. (2013) Molecular Dynamics Simulations and Structure-Based Rational Design Lead to Allosteric HCV NS5B Polymerase Thumb Pocket 2 Inhibitor with Picomolar Cellular Replicon Potency. Journal of Medicinal Chemistry 57:5, pages 1932-1943.
Crossref
Crossref
Pierre L. Beaulieu. 2013. Successful Strategies for the Discovery of Antiviral Drugs. Successful Strategies for the Discovery of Antiviral Drugs
248
294
.
Pierre L. BeaulieuRené CoulombeJames GillardChristian BrochuJianmin DuanMichel GarneauEric JolicoeurPeter KuhnMarc-André PoupartJean RancourtTimothy A. StammersBounkham ThavonekhamGeorge Kukolj. (2013)
Allosteric
N-
acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase — Acylsulfonamides and acylsulfamides as carboxylic acid replacements
. Canadian Journal of Chemistry 91:1, pages 66-81.
Crossref
Crossref
Yuan Kong, Xiaoping Wang, Yushu Shang, Paul M. Schroder, Wenhua Liang, Xiaoting Ling, Zhiyong Guo & Xiaoshun He. (2012) Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis. PLoS ONE 7:12, pages e52158.
Crossref
Crossref
Jonas Kügler, Stefan Schmelz, Juliane Gentzsch, Sibylle Haid, Erik Pollmann, Joop van den Heuvel, Raimo Franke, Thomas Pietschmann, Dirk W. Heinz & John Collins. (2012) High Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant Mutants. Journal of Biological Chemistry 287:46, pages 39224-39232.
Crossref
Crossref
Lenore A. Pelosi, Stacey Voss, Mengping Liu, Min Gao & Julie A. Lemm. (2012) Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir. Antimicrobial Agents and Chemotherapy 56:10, pages 5230-5239.
Crossref
Crossref
Pierre L. Beaulieu, Michael Bös, Michael G. Cordingley, Catherine Chabot, Gulrez Fazal, Michel Garneau, James R. Gillard, Eric Jolicoeur, Steven LaPlante, Ginette McKercher, Martin Poirier, Marc-André Poupart, Youla S. Tsantrizos, Jianmin Duan & George Kukolj. (2012) Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV). Journal of Medicinal Chemistry 55:17, pages 7650-7666.
Crossref
Crossref
Keng‐Hsin Lan, Ying‐Wen Wang, Wei‐Ping Lee, Keng‐Li Lan, Szu‐Han Tseng, Li‐Rong Hung, Sang‐Hue Yen, Han‐Chieh Lin & Shou‐Dong Lee. (2011) Multiple effects of honokiol on the life cycle of hepatitis C virus. Liver International 32:6, pages 989-997.
Crossref
Crossref
Maria Buti & Maria Homs. (2012) Nuevos agentes para el tratamiento de la hepatitis C. Enfermedades Infecciosas y Microbiolog?a Cl?nica 30:3, pages 147-150.
Crossref
Crossref
Smitha Kota, Virginia Takahashi, Feng Ni, John K. Snyder & A. Donny Strosberg. (2012) Direct Binding of a Hepatitis C Virus Inhibitor to the Viral Capsid Protein. PLoS ONE 7:2, pages e32207.
Crossref
Crossref
Daphne M Hotho, Joep de Bruijne, A Marie O'Farrell, Teresa Boyea, Jianke Li, Michele Bracken, Xin Li, David Campbell, Hans-Peter Guler, Christine J Weegink, Janke Schinkel, Richard Molenkamp, Jeroen van de Wetering de Rooij, Andre van Vliet, Harry LA Janssen, Robert J de Knegt & Hendrik W Reesink. (2012) Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design. Antiviral Therapy 17:2, pages 365-375.
Crossref
Crossref
A. A. Butt & F. Kanwal. (2011) Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients. Clinical Infectious Diseases 54:1, pages 96-104.
Crossref
Crossref
Josep Mallolas Masferrer, María Martínez-Rebollar & Montserrat Laguno Centeno. (2011) Tratamiento de la hepatitis por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana. Gastroenterología y Hepatología 34:8, pages 558-567.
Crossref
Crossref
Graham R. Foster, Christophe Hézode, Jean–Pierre Bronowicki, Giampiero Carosi, Ola Weiland, Lieselotte Verlinden, Rolf van Heeswijk, Ben van Baelen, Gaston Picchio & Maria Beumont. (2011) Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections. Gastroenterology 141:3, pages 881-889.e1.
Crossref
Crossref
Lisa S Smith, Michael Nelson, Sagar Naik & Joanna Woten. (2011) Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C. Annals of Pharmacotherapy 45:5, pages 639-648.
Crossref
Crossref
Maria Stepanova, Fasiha Kanwal, Hashem B. El-Serag & Zobair M. Younossi. (2011) Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States. Hepatology 53:3, pages 737-745.
Crossref
Crossref
Yann Benureau, Lucile Warter, Bruce A. Malcolm & Annette Martin. (2010) A comparative analysis of the substrate permissiveness of HCV and GBV-B NS3/4A proteases reveals genetic evidence for an interaction with NS4B protein during genome replication. Virology 406:2, pages 228-240.
Crossref
Crossref
Arthur Donny Strosberg, Smitha Kota, Virginia Takahashi, John K. Snyder & Guillaume Mousseau. (2010) Core as a Novel Viral Target for Hepatitis C Drugs. Viruses 2:8, pages 1734-1751.
Crossref
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:8, pages i-xiii.
Crossref
Crossref
David Bobak. (2010) The Next Era of HCV Antiviral Therapy Finally Begins: Part 1. Current Infectious Disease Reports 12:2, pages 77-78.
Crossref
Crossref
David Bobak. (2010) The Next Era of HCV Antiviral Therapy Finally Begins: Part 2. Current Infectious Disease Reports 12:2, pages 79-80.
Crossref
Crossref
Chun-Hao Chen & Ming-Lung Yu. (2010) Evolution of Interferon-Based Therapy for Chronic Hepatitis C. Hepatitis Research and Treatment 2010, pages 1-12.
Crossref
Crossref